(Q41648126)

6 October 2017

1 reference

title

Treatment of chronic myeloid leukaemia: some topical questions (English)

1 reference

6 October 2017

1 reference

Goldman JM

1

1 reference

6 October 2017

publication date

1 June 1997

1 reference

Best Practice and Research: Clinical Haematology

6 October 2017

published in

1 reference

6 October 2017

volume

10

1 reference

6 October 2017

issue

2

1 reference

6 October 2017

page(s)

405-421

1 reference

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Management of chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Autografting for patients with CML in chronic phase: an update. Hammersmith BMT Team LRF Centre for Adult Leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Report of the Medical Research Council's working party for therapeutic trials in leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Autografting in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Options for therapy in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

Marrow transplantation for the treatment of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980015-7

7 January 2021

10.1016/S0950-3536(97)80015-7

Identifiers

DOI

0 references

1 reference